Market Cap (In ILA)
102.49 Million
Revenue (In ILA)
-
Net Income (In ILA)
-12.04 Million
Avg. Volume
7970.00
- Currency
- ILA
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 430.0-1420.0
- PE
- -3.85
- EPS
- -6.34
- Beta Value
- 0.469
- ISIN
- IL0011284614
- CUSIP
- -
- CIK
- -
- Shares
- 4193690.0
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Mr. Asaf Shiloni
- Employee Count
- -
- Website
- https://www.kadimastem.com
- Ipo Date
- 2013-06-13
- Details
- Kadimastem Ltd, a biopharmaceutical company, develops regenerative medicine therapies based on cells derived from human embryonic stem cells to treat neuro-degenerative diseases. Its products in pipeline include AstroRx, a clinical grade human astrocytes that is in Phase 1/2a clinical trial for the treatment of amyotrophic lateral sclerosis and other neurodegenerative diseases; and IsletRx, a clinical grade pancreatic islet cell therapy treatment for diabetes. The company was incorporated in 2008 and is based in Ness Ziona, Israel.
More Stocks
-
NOVCNova Cannabis Inc.
NOVC
-
WHEELSWheels India Limited
WHEELS
-
TISCO
-
MAU
-
0J72
-
7475ALBIS Co.,Ltd.
7475
-
STGZ
-
6960